Cumulative exposure for 7 days Manufacturer Influenza virus vaccine Fluarix (GlaxoSmithKline) 72 hr Manufacturer Insulin as part (rDNA origin) injection Novolog (Novo Nordisk) 28 days Prescribing ...

double-blind study to compare Fluarix TM with another influenza vaccine. Five open-label, non-randomised studies in high-risk adult populations were performed in selected years from 1995-2000.

The vaccine segment reported 15 per cent Y-o-Y growth, driven by strong growth for Boostrix, Variritix, and Fluarix. In addition, GSK Pharma is intensifying efforts to increase adult immunisation ...